Sinopharm A-Think In-licenses Cancer Drug from Aeterna Zentaris

Sinopharm A-Think Pharma in-licensed greater China rights to a clinical-stage targeted cancer treatment from Aeterna Zentaris, a Canadian biotech. The drug, zoptarelin doxorubicin, is a combination of the well-known chemotherapy doxorubicin and a novel synthetic peptide carrier. It is currently in a Phase III trial for endometrial cancer. SinopharmA-Think made a $1 million upfront payment and is liable for additional payments if the drug achieves specified regulatory and commercial milestones. More details.... Stock Symbols: (NSDQ: AEZS) (TSX: AEZ) Share this with colleagues: // //